RxDoctor Payments Data

Angelica Lozares

Nurse Practitioner · Edinburg, TXNPI 1245261718

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,155 of the $19,386 with a category attached, or 62.7%. 30 manufacturers reported payments, led by Abbott at 25.9% of the total. Among nurse practitioner clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,386in general payments, 2019–2025

Across 388 payments — averaging $49.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Penumbra, Inc.$3K
  • Cardiovascular Systems Inc.$2K
  • Stryker$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Novartis$962
  • plus $5K from 24 others

What the payments were for

  • Travel & lodging$7,15737%
  • Food & beverage$12,15563%
  • Education$750%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,386 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$15,215
Medicare patients
87
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban91$133,358
EliquisApixaban61$78,914
EntrestoSacubitril/Valsartan29$36,414
Ranolazine ErRanolazine41$5,350
Metoprolol Succinate156$2,074
ClopidogrelClopidogrel Bisulfate121$1,175
Cilostazol41$1,120
Atorvastatin Calcium121$1,053
Isosorbide Mononitrate ErIsosorbide Mononitrate98$993
Losartan Potassium61$625
Labetalol Hcl27$618
Nifedipine ErNifedipine18$568
Metoprolol Tartrate69$428
Lisinopril39$426
Nitroglycerin11$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$723$133,35891 claims
PfizerEliquis$331$78,91461 claims
NovartisEntresto$962$36,41429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →